ReviewFEBS letters2014
Recent advances in mammalian protein production.
Review in FEBS letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 220 citations in OpenAlex.
- UniSePT: an engineered broadly applicable Unique Secretory signal PepTide for high-yield biotherapeutic production in mammalian cell-based expression systems.Journal of biological engineering · 2026Article
- Resolving the Interference of Anti-CD38 Antibodies on Blood Compatibility Assays Using CD38 "Baitbodies" Approach.Journal of immunology research · 2026Article
- Engineering bone tissue with mRNA: from molecular design and delivery to clinical applications.Materials today (Kidlington, England) · 2025Article
- Therapeutic Promise and Biotechnological Prospects ofInternational journal of molecular sciences · 2025Review
- Evaluation of anNarra J · 2025Article
- Unveiling the new chapter in nanobody engineering: advances in traditional construction and AI-driven optimization.Journal of nanobiotechnology · 2025Review
- Extracellular vesicle surface engineering with integrins (ITGAL & ITGB2) to specifically target ICAM-1-expressing endothelial cells.Journal of nanobiotechnology · 2025Article
- Updated transient gene expression protocol in Expi293F cells using PEI.Frontiers in bioengineering and biotechnology · 2025Article
- Review
- Site-Specific Integration by Circular Donor Improves CRISPR/Cas9-Mediated Homologous Recombination in Human Cell Lines.International journal of molecular sciences · 2024Article
- Microfluidic Transfection System and Temperature Strongly Influence the Efficiency of Transient Transfection.ACS omega · 2024Article
- Review
- Construction of a novel kinetic model for the production process of a CVA6 VLP vaccine in CHO cells.Cytotechnology · 2024Article
- Mechano-biomimetic hydrogel 3D cell cultivation as a strategy to improve mammalian cell protein expression.Materials today. Bio · 2023Article
- Efficient CRISPR/Cas9-Mediated BAX Gene Ablation in CHO Cells To Impair Apoptosis and Enhance Recombinant Protein Production.Iranian journal of biotechnology · 2023Article
- Construction and application of a multifunctional CHO cell platform utilizing Cre/Frontiers in bioengineering and biotechnology · 2023Article
- Stable expression of shRNA for the control of recombinant adenovirus replication.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Article
- Comparative study of commercial media to improve GMP manufacturing of recombinant human interferon β-1a by CHO cells in perfusion bioreactor.Cytotechnology · 2022Article
- De novo assembly and annotation of the CHOZN® GSBiotechnology and bioengineering · 2022Article
- Generation and Characterization of Stable Redox-Reporter Mammalian Cell Lines of Biotechnological Relevance.Sensors (Basel, Switzerland) · 2022Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mammalian protein production platforms have had a profound impact in many areas of basic and applied research, and an increasing number of blockbuster drugs are recombinant mammalian proteins. With global sales of these drugs exceeding US$120 billion per year, both industry and academic research groups continue to develop cost effective methods for producing mammalian proteins to support pre-clinical and clinical evaluations of potential therapeutics. While a wide range of platforms have been successfully exploited for laboratory use, the bulk of recent biologics have been produced in mammalian cell lines due to the requirement for post translational modification and the biosynthetic complexity of the target proteins. In this review we highlight the range of mammalian expression platforms available for recombinant protein production, as well as advances in technologies for the rapid and efficient selection of highly productive clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.